What top creators are saying about Hims & Hers Health, Inc.(HIMS)

The company announced plans to launch peptides, but the stock fell more than 11%. The speaker saw the decline as unrelated to the news, while the commercial impact and regulatory context remained unclear.

The speaker sees potential growth tied to the planned peptide offerings and considers the roughly 16% two-day decline disconnected from the positive company news, while noting broader market volatility.

Hims & Hers was mentioned in the market rundown as a price-action snapshot, without an accompanying investment thesis.

The stock reportedly fell 10% after a CEO announcement investors had been anticipating, illustrating that expected company news may not produce a positive share-price reaction.

The speaker considers Hims inexpensive and sees potential in its medically supervised peptide offering and cross-selling to existing customers, but pricing and customer demand remain uncertain.

Mentioned only as an example of a stock that performed worse during the selloff; no company-specific analysis or recommendation was provided.

The speaker is bullish on the potential importance of a peptide-related product launch, while noting the stock fell 2.3% after hours despite the news and that commercial impact remains uncertain.

The speaker is strongly bullish, viewing a potential peptide offering, international expansion, and existing U.S. manufacturing capabilities as growth catalysts that may put revenue above the company's $6.5 billion 2030 guidance. The peptide opportunity remains speculative amid regulatory, competition, market-size, and earnings uncertainties.

Mentioned only as a valuation comparison for SpaceX; no company outlook or investment thesis was provided.

The stock fell about 5% amid broad market selling despite no substantial company news. The speaker cited revenue growth near 40% and described the valuation as very low, while noting that the valuation measure behind a figure of 0.1 was unspecified.

The stock was down about 10% in the broad risk-asset sell-off, which the speaker said may obscure company-specific fundamentals; no separate valuation view or recommendation was given.

The speaker uses Hims & Hers as an example of a growth stock previously considered cheap and says its decline, despite little connection to AI news, supports the view that broader contagion affected growth stocks.

The speaker called the stock cheap by an unspecified valuation measure, while noting its price action was sensitive to broad risk-on and risk-off swings.

The positive case rests on strong revenue growth, product opportunities including GLP-1 offerings, and international expansion. The speaker cited 17-fold revenue growth in about six years and a Rule of 40 score of 46, while noting that shares still fell nearly 6%.

Mentioned as an example of a company that used convertible financing on favorable terms in 2025; no separate investment thesis is provided.

The author sold the position for a realized gain of 0.66%.

The author sold the stock for a 0.66% realized gain.

Described as consolidating and potentially volatile around upcoming catalysts.

The ad highlights consumer access to GLP-1 treatments but offers no assessment of the company's outlook, valuation, or risks, and is not a buy recommendation.

The stock was among those that fell; the discussion provided no specific company analysis.

Shares rose about 10%. A speaker expected free cash flow to turn positive in the second half after being negative in the first half, but described the position as a trade, acknowledged limited research, and noted uncertainty around a peptide-related lawsuit.

The host sees HIMS as a possible opportunity after a roughly 5% decline, citing cash flow, SaaS-like economics, its GLP-1 prescription business, and potential peptide sales. Venture investments and prospective catalysts could add value, but their returns and timing are uncertain.

Mentioned among healthcare stocks gaining, without specific company-level results or detailed analysis.

The speaker said he had no opinion on the stock.

A sponsored segment promoted access to weight-loss care, including Wegovy, but provided no financial analysis or investment outlook.

Used only as a comparison for Micron’s low reading on the speaker’s valuation metric; no separate investment thesis is provided.

Shares rose, but the host cited regulatory and legal uncertainty and questioned whether the company has a durable moat beyond marketing.

Discussed as an example of a public company connected to an on-chain meme-token community. The speaker claimed on-chain trading once reached roughly 10% of HIMS stock trading volume, but the proposed marketing and tokenization benefits remain experimental.

The speaker is bullish, citing sales growth, a valuation of about 2x forward revenue, and potential growth from international expansion, branded GLP-1 products, additional services, and an AI-native care experience. Risks include uncertain adoption and approvals, investment needs, and lower EBITDA margins.

The stock has faced broad growth-stock selling and was described as having traded at a low valuation for an extended period; the speaker says to assess its business performance rather than infer fundamentals from price action.

Mentioned as the company referenced by the Boner meme-token theme; no analysis or stock recommendation is provided.

A memecoin was associated with Hims' men’s-health business and a claimed social-media interaction, but no formal company connection or stock recommendation was established.

About 30% of its float was reportedly shorted, which could attract speculative short-squeeze trading, but no squeeze was established as likely. Tokenized stock activity was small relative to the company.

Hims & Hers is referenced as the company behind Bonacoin's theme, with no stock analysis or recommendation.

The speaker described a past short trade that worked well but said he was not currently short and gave no longer-term view.

Presents an attractive entry point driven by strong top-line revenue growth, wearable development, and a distribution partnership role with Novo Nordisk for weight-loss drugs.

Fundamentally undervalued with an attractive Gross Profit over Revenue Growth ratio around 0.1, making it a compelling long-term opportunity despite interest rate-driven drawdowns.

An undervalued growth asset with upcoming catalysts including a full mobile application redesign and international platform integration.

Experiencing strong consumer demand by providing direct access to affordable GLP-1 weight-loss options and bypassing traditional insurance friction via recurring subscriptions.

Despite moving within a 20% volatility band, the valuation is considered way too cheap relative to underlying fundamentals, presenting an attractive entry point for long-term investors.

Highlighted through an on-chain MemeFi tokenized liquidity pair that gained public visibility following engagement from the company's CEO.

Tokenized trading volume remains too negligible relative to its $6.5 billion market cap to influence traditional equity price action or trigger short squeezes.

Tokenized stock traded up to $132 on weekend AMM pools due to severe liquidity imbalances, highlighting counterparty and redemption risks.

Capturing market share in high-demand categories like weight loss and GLP-1 access through end-to-end online visits and direct-to-door delivery.

On-chain paired token demand forces liquidity providers to mint new tokenized shares, translating into real 1:1 backed off-chain share purchases and increased retail search volume.

Recent 18% pullback offers long-term upside driven by an EV/GP/RG ratio of 0.1, a Rule of 40 score of 46, and strong positioning for 2026-2027 peptide distribution approvals.

Highlighted for extreme price dislocations and volatility caused by unbacked on-chain tokenized trading pools outside traditional market hours.

Represents a deep-value opportunity trading at a discounted 0.10 valuation multiple despite resilient underlying fundamentals.

Tokenized pairings with meme coins carry severe volatility and liquidity risks, with retail facing downside risk from inefficient on-chain arbitrage against the underlying equity.

Telehealth stock valued around $6 billion paired with the BONER meme coin in the stock-meme trend.